CSIMarket


Altamira Therapeutics Ltd   (CYTO)
Other Ticker:  
 


 

Altamira Therapeutics Ltd

CYTO's Financial Statements and Analysis



Altamira Therapeutics Ltd reported break-even for the forth quarter of 2023 compare to net loss per share of $-582.60 recorded in the same quarter a year ago an improvement compare to $0.00 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ 0 $  0 Mill
$+582.60     Unch.    



Altamira Therapeutics Ltd 's Revenue fell by 0 % in forth quarter of 2023 (Dec 31 2023) year on year, to $0 million and declined by sequentially.


Altamira Therapeutics Ltd is

More on CYTO's Income Statement



Altamira Therapeutics Ltd in the forth quarter of 2023 recorded net loss of $0.000 million, an improvement compare to net loss of $-26.528 million in IV. Quarter a year ago.

Sequentially net loss narrowed from net loss of $0.000 million realized in previous quarter.

More on CYTO's Growth

Altamira Therapeutics Ltd Inventories
CYTO's Cash flow In the forth quarter of 2023 company's net cash flow was $0 million


Altamira Therapeutics Ltd






More on CYTO's Dividends

 Market Capitalization (Millions) -
 Shares Outstanding (Millions) -
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Altamira Therapeutics Ltd






More on CYTO's Balance Sheets

 Market Capitalization (Millions) -
 Shares Outstanding (Millions) -
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Altamira Therapeutics Ltd Earnings